Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHCZ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,673
Award facts
- Contract value 100% obligated
- $25,673.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $25,673.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 30, 2026, and carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support Department of Defense pharmaceutical supply needs globally.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical supplier within the federal military medical supply chain since its initial SAM registration in 2001. The company's broader PPV-G GEN V prime vendor contract, valued at $499,999,999 and effective through December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. This particular delivery order for EXPAREL, a specialty surgical pharmaceutical used for pain management, exemplifies the vendor's role in supplying specialized therapeutic products to support Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHCZ5?
SPE2DR26FHCZ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FHCZ5 worth?
The government has obligated $25,673 on SPE2DR26FHCZ5.
Is contract SPE2DR26FHCZ5 an order under another contract?
Yes. SPE2DR26FHCZ5 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCZ5 competed?
The extent of competition for SPE2DR26FHCZ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award